{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:01:29Z","timestamp":1792677689653,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s11864-021-00861-0","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T12:10:09Z","timestamp":1623067809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multidisciplinary Management of Adolescent and Young Adult Patients with Hodgkin Lymphoma"],"prefix":"10.1007","volume":"22","author":[{"given":"Emily","family":"Galloway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-3163","authenticated-orcid":false,"given":"Allison","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"861_CR1","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Hodgkin lymphoma. Bethesda, MD. 2017. https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html. Accessed March 5 2021."},{"issue":"24","key":"861_CR2","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1002\/cncr.27684","volume":"118","author":"EC Smith","year":"2012","unstructured":"Smith EC, Ziogas A, Anton-Culver H. Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer. 2012;118(24):6179\u201387. https:\/\/doi.org\/10.1002\/cncr.27684.","journal-title":"Cancer."},{"issue":"2","key":"861_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/1055-9965.Epi-15-0756","volume":"25","author":"TH Keegan","year":"2016","unstructured":"Keegan TH, DeRouen MC, Parsons HM, Clarke CA, Goldberg D, Flowers CR, et al. Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin lymphoma: a population-based study. Cancer Epidemiol Biomarkers Prev. 2016;25(2):264\u201373. https:\/\/doi.org\/10.1158\/1055-9965.Epi-15-0756.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"6","key":"861_CR4","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/leu.2017.66","volume":"31","author":"J Wolfson","year":"2017","unstructured":"Wolfson J, Sun CL, Wyatt L, Stock W, Bhatia S. Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma. Leukemia. 2017;31(6):1450\u20133. https:\/\/doi.org\/10.1038\/leu.2017.66.","journal-title":"Leukemia."},{"key":"861_CR5","doi-asserted-by":"publisher","unstructured":"\u2022 Phillips CR, Haase JE, Broome ME, Carpenter JS, Frankel RM. Connecting with healthcare providers at diagnosis: adolescent\/young adult cancer survivors' perspectives. Int J Qual Stud Health Well-being. 2017;12(1):1325699. https:\/\/doi.org\/10.1080\/17482631.2017.1325699. This study provides awareness of the importance of early connection with the healthcare team for AYAs. It is unique in that it also suggests actions and behaviors that can promote or hinder such a connection.","DOI":"10.1080\/17482631.2017.1325699"},{"issue":"10","key":"861_CR6","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","volume":"114","author":"CL Schwartz","year":"2009","unstructured":"Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051\u20139. https:\/\/doi.org\/10.1182\/blood-2008-10-184143.","journal-title":"Blood."},{"issue":"26","key":"861_CR7","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1200\/jco.2011.41.1819","volume":"30","author":"SL Wolden","year":"2012","unstructured":"Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J, et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group. J Clin Oncol. 2012;30(26):3174\u201380. https:\/\/doi.org\/10.1200\/jco.2011.41.1819.","journal-title":"J Clin Oncol."},{"issue":"32","key":"861_CR8","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/jco.2013.52.5410","volume":"32","author":"DL Friedman","year":"2014","unstructured":"Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014;32(32):3651\u20138. https:\/\/doi.org\/10.1200\/jco.2013.52.5410.","journal-title":"J Clin Oncol."},{"issue":"7","key":"861_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Pl\u00fctschow A, Eich HT, Lohri A, D\u00f6rken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1000067.","journal-title":"N Engl J Med."},{"issue":"16","key":"861_CR10","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/jco.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 Trial. J Clin Oncol. 2017;35(16):1786\u201394. https:\/\/doi.org\/10.1200\/jco.2016.68.6394.","journal-title":"J Clin Oncol."},{"issue":"31","key":"861_CR11","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/jco.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J Clin Oncol. 2019;37(31):2835\u201345. https:\/\/doi.org\/10.1200\/jco.19.00964.","journal-title":"J Clin Oncol."},{"issue":"25","key":"861_CR12","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Foss\u00e5 A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374(25):2419\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1510093.","journal-title":"N Engl J Med."},{"issue":"4","key":"861_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378(4):331\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1708984.","journal-title":"N Engl J Med."},{"issue":"10","key":"861_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood.2019003127","volume":"135","author":"DJ Straus","year":"2020","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Alekseev S, Ill\u00e9s \u00c1, Picardi M, Lech-Maranda E, et al. Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020;135(10):735\u201342. https:\/\/doi.org\/10.1182\/blood.2019003127.","journal-title":"Blood."},{"issue":"17","key":"861_CR15","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(17):1598\u2013607. https:\/\/doi.org\/10.1056\/NEJMoa1408648.","journal-title":"N Engl J Med."},{"issue":"2","key":"861_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/s1470-2045(18)30784-8","volume":"20","author":"RO Casasnovas","year":"2019","unstructured":"Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202\u201315. https:\/\/doi.org\/10.1016\/s1470-2045(18)30784-8.","journal-title":"Lancet Oncol."},{"issue":"9","key":"861_CR17","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/jco.2011.38.5807","volume":"30","author":"B von Tresckow","year":"2012","unstructured":"von Tresckow B, Pl\u00fctschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol. 2012;30(9):907\u201313. https:\/\/doi.org\/10.1200\/jco.2011.38.5807.","journal-title":"J Clin Oncol."},{"issue":"8","key":"861_CR18","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1080\/1042819042000209404","volume":"45","author":"L Yung","year":"2004","unstructured":"Yung L, Smith P, Hancock BW, Hoskin P, Gilson D, Vernon C, et al. Long term outcome in adolescents with Hodgkin's lymphoma: poor results using regimens designed for adults. Leuk Lymphoma. 2004;45(8):1579\u201385. https:\/\/doi.org\/10.1080\/1042819042000209404.","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"861_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/cncr.30979","volume":"124","author":"SK Parsons","year":"2018","unstructured":"Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, et al. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: an adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer. 2018;124(1):136\u201344. https:\/\/doi.org\/10.1002\/cncr.30979.","journal-title":"Cancer."},{"issue":"36","key":"861_CR20","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.1200\/jco.2008.20.2655","volume":"27","author":"DA Eichenauer","year":"2009","unstructured":"Eichenauer DA, Bredenfeld H, Haverkamp H, M\u00fcller H, Franklin J, Fuchs M, et al. Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group. J Clin Oncol. 2009;27(36):6079\u201385. https:\/\/doi.org\/10.1200\/jco.2008.20.2655.","journal-title":"J Clin Oncol."},{"key":"861_CR21","doi-asserted-by":"publisher","unstructured":"Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;(6):Cd009411. https:\/\/doi.org\/10.1002\/14651858.CD009411.pub2.","DOI":"10.1002\/14651858.CD009411.pub2"},{"issue":"9","key":"861_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00277-016-2736-5","volume":"95","author":"S Akhtar","year":"2016","unstructured":"Akhtar S, Rauf SM, Elhassan TA, Maghfoor I. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma. Ann Hematol. 2016;95(9):1521\u201335. https:\/\/doi.org\/10.1007\/s00277-016-2736-5.","journal-title":"Ann Hematol."},{"issue":"4","key":"861_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1411087.","journal-title":"N Engl J Med."},{"issue":"19","key":"861_CR24","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/jco.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125\u201332. https:\/\/doi.org\/10.1200\/jco.2016.72.1316.","journal-title":"J Clin Oncol."},{"issue":"18","key":"861_CR25","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/jco.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183\u20139. https:\/\/doi.org\/10.1200\/jco.2011.38.0410.","journal-title":"J Clin Oncol."},{"issue":"10","key":"861_CR26","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/s2352-3026(18)30153-4","volume":"5","author":"F Locatelli","year":"2018","unstructured":"Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study. Lancet Haematol. 2018;5(10):e450\u2013e61. https:\/\/doi.org\/10.1016\/s2352-3026(18)30153-4.","journal-title":"Lancet Haematol."},{"issue":"4","key":"861_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020;21(4):541\u201350. https:\/\/doi.org\/10.1016\/s1470-2045(20)30023-1.","journal-title":"Lancet Oncol."},{"issue":"1","key":"861_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s1470-2045(19)30671-0","volume":"21","author":"B Geoerger","year":"2020","unstructured":"Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020;21(1):121\u201333. https:\/\/doi.org\/10.1016\/s1470-2045(19)30671-0.","journal-title":"Lancet Oncol."},{"issue":"26","key":"861_CR29","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med."},{"issue":"1","key":"861_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med."},{"issue":"14","key":"861_CR31","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347.","journal-title":"N Engl J Med."},{"issue":"5 Suppl","key":"861_CR32","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/pbc.21459","volume":"50","author":"A Ferrari","year":"2008","unstructured":"Ferrari A, Montello M, Budd T, Bleyer A. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr Blood Cancer. 2008;50(5 Suppl):1101\u20134. https:\/\/doi.org\/10.1002\/pbc.21459.","journal-title":"Pediatr Blood Cancer."},{"issue":"19","key":"861_CR33","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1200\/jco.2018.78.1914","volume":"36","author":"K Oktay","year":"2018","unstructured":"\u2022 Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994\u20132001. https:\/\/doi.org\/10.1200\/jco.2018.78.1914. This systematic review thoroughly compiles current recommendations for fertility preservation in patients with cancer, both pediatric and adult. It also provides guidance on fertility counseling in the setting of oncology.","journal-title":"J Clin Oncol"},{"issue":"3","key":"861_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.6004\/jnccn.2016.0035","volume":"14","author":"JM Salsman","year":"2016","unstructured":"Salsman JM, Yanez B, Smith KN, Beaumont JL, Snyder MA, Barnes K, et al. Documentation of fertility preservation discussions for young adults with cancer: examining compliance with treatment guidelines. J Natl Compr Canc Netw. 2016;14(3):301\u20139. https:\/\/doi.org\/10.6004\/jnccn.2016.0035.","journal-title":"J Natl Compr Canc Netw."},{"issue":"7","key":"861_CR35","doi-asserted-by":"publisher","first-page":"e2010806","DOI":"10.1001\/jamanetworkopen.2020.10806","volume":"3","author":"P Patel","year":"2020","unstructured":"Patel P, Kohn TP, Cohen J, Shiff B, Kohn J, Ramasamy R. Evaluation of reported fertility preservation counseling before chemotherapy using the quality oncology practice initiative survey. JAMA Netw Open. 2020;3(7):e2010806. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.10806.","journal-title":"JAMA Netw Open."},{"issue":"32","key":"861_CR36","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1200\/jco.2009.22.8312","volume":"28","author":"J Levine","year":"2010","unstructured":"Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4831\u201341. https:\/\/doi.org\/10.1200\/jco.2009.22.8312.","journal-title":"J Clin Oncol."},{"issue":"11","key":"861_CR37","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/annonc\/mdz284","volume":"30","author":"M Salama","year":"2019","unstructured":"Salama M, Anazodo A, Woodruff TK. Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach. Ann Oncol. 2019;30(11):1760\u201375. https:\/\/doi.org\/10.1093\/annonc\/mdz284.","journal-title":"Ann Oncol."},{"key":"861_CR38","doi-asserted-by":"publisher","unstructured":"Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37\u201343. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.09.028.","DOI":"10.1016\/j.fertnstert.2012.09.028"},{"issue":"4","key":"861_CR39","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/hon.939","volume":"28","author":"MA van der Kaaij","year":"2010","unstructured":"van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC. Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol. 2010;28(4):168\u201379. https:\/\/doi.org\/10.1002\/hon.939.","journal-title":"Hematol Oncol."},{"key":"861_CR40","doi-asserted-by":"publisher","unstructured":"De Bruin ML, Huisbrink J, Hauptmann M, Kuenen MA, Ouwens GM, van't Veer MB et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood. 2008;111(1):101-108. https:\/\/doi.org\/10.1182\/blood-2007-05-090225.","DOI":"10.1182\/blood-2007-05-090225"},{"issue":"2","key":"861_CR41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/jco.2012.44.3721","volume":"31","author":"K Behringer","year":"2013","unstructured":"Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231\u20139. https:\/\/doi.org\/10.1200\/jco.2012.44.3721.","journal-title":"J Clin Oncol."},{"key":"861_CR42","doi-asserted-by":"publisher","unstructured":"Sieniawski M, Reineke T, Nogova L, Josting A, Pfistner B, Diehl V et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin study group (GHSG). Blood. 2008;111(1):71-76. https:\/\/doi.org\/10.1182\/blood-2007-02-073544.","DOI":"10.1182\/blood-2007-02-073544"},{"key":"861_CR43","volume-title":"Identifying and addressing the needs of adolescents and young adults with cancer: workshop summary","author":"Medicine Io","year":"2013","unstructured":"Medicine Io. Identifying and addressing the needs of adolescents and young adults with cancer: workshop summary. Washington, DC: The National Academies Press; 2013."},{"key":"861_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fonc.2013.00075","volume":"3","author":"AW Smith","year":"2013","unstructured":"Smith AW, Parsons HM, Kent EE, Bellizzi K, Zebrack BJ, Keel G, et al. Unmet support service needs and health-related quality of life among adolescents and young adults with Cancer: The AYA HOPE Study. Front Oncol. 2013;3:75. https:\/\/doi.org\/10.3389\/fonc.2013.00075.","journal-title":"Front Oncol."},{"key":"861_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1477-7525-8-25","volume":"8","author":"T Clinton-McHarg","year":"2010","unstructured":"Clinton-McHarg T, Carey M, Sanson-Fisher R, Shakeshaft A, Rainbird K. Measuring the psychosocial health of adolescent and young adult (AYA) cancer survivors: a critical review. Health and quality of life outcomes. 2010;8:25. https:\/\/doi.org\/10.1186\/1477-7525-8-25.","journal-title":"Health and quality of life outcomes."},{"issue":"1","key":"861_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00520-016-3396-7","volume":"25","author":"CK Cheung","year":"2017","unstructured":"Cheung CK, Zebrack B. What do adolescents and young adults want from cancer resources? Insights from a Delphi panel of AYA patients. Support Care Cancer. 2017;25(1):119\u201326. https:\/\/doi.org\/10.1007\/s00520-016-3396-7.","journal-title":"Support Care Cancer."},{"issue":"3","key":"861_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.15241\/jzt.7.3.259","volume":"7","author":"J Taylor","year":"2017","unstructured":"\u2022 Taylor J, Susan K-W. Counseling preferences of young adults with cancer. Professional Counselor. 2017;7(3):259\u201371. https:\/\/doi.org\/10.15241\/jzt.7.3.259. An online survey was completed by over 300 AYAs with cancer to evaluate psychosocial needs and preferred types of counseling. Results indicate individual and group counseling would be acceptable depending on the topics being discussed.","journal-title":"Professional Counselor"},{"issue":"4","key":"861_CR48","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00520-017-3937-8","volume":"26","author":"G Lopez","year":"2018","unstructured":"Lopez G, Liu W, Madden K, Fellman B, Li Y, Bruera E. Adolescent-young adults (AYA) with cancer seeking integrative oncology consultations: demographics, characteristics, and self-reported outcomes. Support Care Cancer. 2018;26(4):1161\u20137. https:\/\/doi.org\/10.1007\/s00520-017-3937-8.","journal-title":"Support Care Cancer."},{"key":"861_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.REO.0000000000000158","volume":"37","author":"A Smith","year":"2018","unstructured":"Smith A, Murnane A, Thompson K, Mancuso S. ReActivate\u2014a goal-orientated rehabilitation program for adolescent and young adult cancer survivors. Rehabilitation Oncology. 2018;37:1. https:\/\/doi.org\/10.1097\/01.REO.0000000000000158.","journal-title":"Rehabilitation Oncology."},{"issue":"14","key":"861_CR50","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/jnci\/djq238","volume":"102","author":"DL Friedman","year":"2010","unstructured":"Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083\u201395. https:\/\/doi.org\/10.1093\/jnci\/djq238.","journal-title":"J Natl Cancer Inst."},{"key":"861_CR51","doi-asserted-by":"publisher","unstructured":"Howell CR, Bjornard KL, Ness KK, Alberts N, Armstrong GT, Bhakta N, et al. Cohort Profile: The St. Jude Lifetime Cohort Study (SJLIFE) for paediatric cancer survivors. Int J Epidemiol. 2020. https:\/\/doi.org\/10.1093\/ije\/dyaa203.","DOI":"10.1093\/ije\/dyaa203"},{"issue":"1","key":"861_CR52","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/asheducation-2016.1.323","volume":"2016","author":"FE van Leeuwen","year":"2016","unstructured":"van Leeuwen FE, Ng AK. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program. 2016;2016(1):323\u201330. https:\/\/doi.org\/10.1182\/asheducation-2016.1.323.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"8","key":"861_CR53","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1080\/10428194.2017.1406086","volume":"59","author":"J Fu","year":"2018","unstructured":"Fu J, Upshaw J, Cohen J, Rodday AM, Saunders T, Kelly M, et al. Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review. Leuk Lymphoma. 2018;59(8):1976\u201380. https:\/\/doi.org\/10.1080\/10428194.2017.1406086.","journal-title":"Leuk Lymphoma."},{"issue":"23","key":"861_CR54","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","volume":"61","author":"C Jaworski","year":"2013","unstructured":"Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol. 2013;61(23):2319\u201328. https:\/\/doi.org\/10.1016\/j.jacc.2013.01.090.","journal-title":"J Am Coll Cardiol."},{"issue":"30","key":"861_CR55","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1200\/jco.2005.02.7243","volume":"23","author":"WG Martin","year":"2005","unstructured":"Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005;23(30):7614\u201320. https:\/\/doi.org\/10.1200\/jco.2005.02.7243.","journal-title":"J Clin Oncol."},{"issue":"3","key":"861_CR56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.seminhematol.2016.05.008","volume":"53","author":"AK Ng","year":"2016","unstructured":"Ng AK, van Leeuwen FE. Hodgkin lymphoma: Late effects of treatment and guidelines for surveillance. Semin Hematol. 2016;53(3):209\u201315. https:\/\/doi.org\/10.1053\/j.seminhematol.2016.05.008.","journal-title":"Semin Hematol."},{"issue":"5","key":"861_CR57","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/ijc.26086","volume":"130","author":"G Brabant","year":"2012","unstructured":"Brabant G, Toogood AA, Shalet SM, Frobisher C, Lancashire ER, Reulen RC, et al. Hypothyroidism following childhood cancer therapy-an under diagnosed complication. Int J Cancer. 2012;130(5):1145\u201350. https:\/\/doi.org\/10.1002\/ijc.26086.","journal-title":"Int J Cancer."},{"issue":"1","key":"861_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/hon.802","volume":"25","author":"DC Hodgson","year":"2007","unstructured":"Hodgson DC, Pintilie M, Gitterman L, Dewitt B, Buckley CA, Ahmed S, et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol. 2007;25(1):11\u20135. https:\/\/doi.org\/10.1002\/hon.802.","journal-title":"Hematol Oncol."},{"issue":"12","key":"861_CR59","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/s1470-2045(09)70258-x","volume":"10","author":"N Heutte","year":"2009","unstructured":"Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, et al. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol. 2009;10(12):1160\u201370. https:\/\/doi.org\/10.1016\/s1470-2045(09)70258-x.","journal-title":"Lancet Oncol."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00861-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T13:41:48Z","timestamp":1623418908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00861-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00861-0","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"31 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Emily Galloway declares that she has no conflict of interest. Melody Griffith declares that she has no conflict of interest. Allison Rosenthal declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"64"}}